Clinical trial
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for…
NCT00219765 · Poitiers University Hospital, Other · Terminated
Key facts
| NCT number | NCT00219765 |
|---|---|
| Title | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients |
| Official title | Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase |
| Lead sponsor | Poitiers University Hospital, Other |
| Collaborators | Ministry of Health, France Novartis Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate 600 mg, Cytarabine, Daunorubicine |
| Enrollment | 30 |
| Start date | May 1, 2001 |
| Completion | Jan 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 28, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: